RU2765181C2 - Полиморфная форма диарильного макроцикла - Google Patents

Полиморфная форма диарильного макроцикла Download PDF

Info

Publication number
RU2765181C2
RU2765181C2 RU2018104269A RU2018104269A RU2765181C2 RU 2765181 C2 RU2765181 C2 RU 2765181C2 RU 2018104269 A RU2018104269 A RU 2018104269A RU 2018104269 A RU2018104269 A RU 2018104269A RU 2765181 C2 RU2765181 C2 RU 2765181C2
Authority
RU
Russia
Prior art keywords
cancer
compound
present
formula
carcinoma
Prior art date
Application number
RU2018104269A
Other languages
English (en)
Russian (ru)
Other versions
RU2018104269A (ru
RU2018104269A3 (enExample
Inventor
Цзинжун Дж. ЦУЙ
Эван В. РОДЖЕРС
Original Assignee
Тёрнинг Поинт Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тёрнинг Поинт Терапьютикс, Инк. filed Critical Тёрнинг Поинт Терапьютикс, Инк.
Publication of RU2018104269A publication Critical patent/RU2018104269A/ru
Publication of RU2018104269A3 publication Critical patent/RU2018104269A3/ru
Application granted granted Critical
Publication of RU2765181C2 publication Critical patent/RU2765181C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
RU2018104269A 2015-07-06 2016-07-05 Полиморфная форма диарильного макроцикла RU2765181C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US62/188,846 2015-07-06
US201562218672P 2015-09-15 2015-09-15
US62/218,672 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (3)

Publication Number Publication Date
RU2018104269A RU2018104269A (ru) 2019-08-06
RU2018104269A3 RU2018104269A3 (enExample) 2019-12-17
RU2765181C2 true RU2765181C2 (ru) 2022-01-26

Family

ID=57685592

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018104269A RU2765181C2 (ru) 2015-07-06 2016-07-05 Полиморфная форма диарильного макроцикла

Country Status (24)

Country Link
US (5) US10294242B2 (enExample)
EP (2) EP3319969B1 (enExample)
JP (2) JP6917974B2 (enExample)
KR (1) KR102623734B1 (enExample)
CN (2) CN108026108B (enExample)
AU (1) AU2016289454B2 (enExample)
BR (1) BR112018000297A2 (enExample)
CA (1) CA2990020C (enExample)
DK (1) DK3319969T3 (enExample)
ES (1) ES2979111T3 (enExample)
FI (1) FI3319969T3 (enExample)
HR (1) HRP20240780T1 (enExample)
HU (1) HUE067352T2 (enExample)
IL (2) IL256443B (enExample)
LT (1) LT3319969T (enExample)
MX (2) MX386680B (enExample)
PL (1) PL3319969T3 (enExample)
PT (1) PT3319969T (enExample)
RS (1) RS65593B1 (enExample)
RU (1) RU2765181C2 (enExample)
SI (1) SI3319969T1 (enExample)
SM (1) SMT202400213T1 (enExample)
WO (1) WO2017007759A1 (enExample)
ZA (1) ZA201708436B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
HRP20240780T1 (hr) 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
KR102772574B1 (ko) * 2015-07-21 2025-02-24 터닝 포인트 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
JP7224334B2 (ja) * 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
EP3770161B1 (en) * 2018-04-16 2022-08-24 Shenzhen TargetRx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CN113727984B (zh) 2019-05-21 2024-03-15 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CA3143043A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
CA3163095A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
KR20220133866A (ko) * 2019-11-27 2022-10-05 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로시클릭 화합물을 수반하는 병용 요법
IL295938A (en) * 2020-03-02 2022-10-01 Turning Point Therapeutics Inc Therapeutic uses of macrocyclic compounds
EP4148055A4 (en) * 2020-05-08 2023-10-11 Shandong Xuanzhu Pharma Co., Ltd. CRYSTAL FORM OF A MACROCYCLIC TYROSINE KINASE INHIBITOR AND PROCESS FOR PRODUCTION THEREOF
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100450A1 (ru) * 2008-09-08 2011-10-31 Мерк Патент Гмбх Макроциклические пирамидины в качестве ингибиторов протеинкиназы
US20130203776A1 (en) * 2010-05-20 2013-08-08 Steven Wade Andrews Macrocyclic compounds as trk kinase inhibitors
US20130245021A1 (en) * 2012-03-09 2013-09-19 Yingzhi Bi IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
US20140206605A1 (en) * 2011-08-19 2014-07-24 Gregory L. Beutner Crystal forms of a hcv protease inhibitor

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
DE3861031D1 (de) 1987-03-07 1990-12-20 Bayer Ag Verfahren zur herstellung von 5-amino-4,6-dihalogenpyridinen.
DK0690843T3 (da) 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
CN1050844C (zh) 1993-12-07 2000-03-29 伊莱利利公司 蛋白激酶ｃ抑制剂
GB9403639D0 (en) * 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
CN1277828C (zh) 2000-07-31 2006-10-04 霍夫曼-拉罗奇有限公司 哌嗪衍生物
US6828327B2 (en) 2000-12-08 2004-12-07 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
UA91698C2 (ru) * 2005-01-10 2010-08-25 Арена Фармасьютікалз, Інк. Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
US8960547B2 (en) 2007-09-19 2015-02-24 E-Seek, Inc. Document scanner with instant retrieval process
US8270176B2 (en) 2008-08-08 2012-09-18 Stats Chippac Ltd. Exposed interconnect for a package on package system
TWM352384U (en) 2008-08-22 2009-03-11 Luff Technology Co Ltd Wireless detection device for club and system thereof
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
JP5769199B2 (ja) 2008-10-31 2015-08-26 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
GB2482674B (en) 2010-08-09 2012-08-22 Rolls Royce Plc An aerofoil, an aerofoil sub-assembly and a method of making the same
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2541470B1 (en) 2011-06-29 2017-10-04 Denso Wave Incorporated Information code and information code reader
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
KR20140078710A (ko) 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
WO2013132376A1 (en) 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
RU2014140735A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US9682995B2 (en) 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
CN105358534A (zh) 2013-04-23 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20150112816A1 (en) * 2013-10-21 2015-04-23 Disney Enterprises, Inc. Systems and methods for providing a graphical user interface for providing brand integration within online content, managing brand integration within online content, and/or managing compensation associated with online content
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
BR202014004079U2 (pt) 2014-02-21 2015-10-27 Mix For You Ltda higienizador íntimo
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
EP4420732A3 (en) 2014-12-15 2024-11-27 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
WO2016143189A1 (ja) 2015-03-09 2016-09-15 住友ゴム工業株式会社 タイヤ
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
CA2984848A1 (en) 2015-05-05 2016-11-10 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US9524416B1 (en) 2015-07-03 2016-12-20 Fingerprint Cards Ab Fingerprint sensing device comprising three-dimensional pattern
HRP20240780T1 (hr) * 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
US10239565B2 (en) 2015-07-17 2019-03-26 John Michael Baker Pickup truck tailgate lifting apparatus
KR102772574B1 (ko) 2015-07-21 2025-02-24 터닝 포인트 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
JP6580495B2 (ja) 2016-02-02 2019-09-25 三菱重工業株式会社 保持治具
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
EP3555137A1 (en) 2016-12-14 2019-10-23 Development Center for Biotechnology Antibody-drug conjugates and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100450A1 (ru) * 2008-09-08 2011-10-31 Мерк Патент Гмбх Макроциклические пирамидины в качестве ингибиторов протеинкиназы
US20130203776A1 (en) * 2010-05-20 2013-08-08 Steven Wade Andrews Macrocyclic compounds as trk kinase inhibitors
US20140206605A1 (en) * 2011-08-19 2014-07-24 Gregory L. Beutner Crystal forms of a hcv protease inhibitor
US20130245021A1 (en) * 2012-03-09 2013-09-19 Yingzhi Bi IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Also Published As

Publication number Publication date
JP2021119151A (ja) 2021-08-12
HUE067352T2 (hu) 2024-10-28
DK3319969T3 (da) 2024-07-08
IL283184A (en) 2021-06-30
CN108026108B (zh) 2021-06-22
US20190233437A1 (en) 2019-08-01
US20180194777A1 (en) 2018-07-12
CN113354653B (zh) 2024-12-31
EP3319969A4 (en) 2019-07-03
US20250223298A1 (en) 2025-07-10
AU2016289454A1 (en) 2018-01-04
RU2018104269A (ru) 2019-08-06
PT3319969T (pt) 2024-06-17
MX386680B (es) 2025-03-19
IL256443A (en) 2018-02-28
JP2018529633A (ja) 2018-10-11
JP7212713B2 (ja) 2023-01-25
AU2016289454B2 (en) 2020-07-09
HK1254492A1 (zh) 2019-07-19
HRP20240780T1 (hr) 2024-09-13
CN108026108A (zh) 2018-05-11
PL3319969T3 (pl) 2024-06-24
KR102623734B1 (ko) 2024-01-10
ZA201708436B (en) 2021-03-31
US20230295184A1 (en) 2023-09-21
CA2990020A1 (en) 2017-01-12
RU2018104269A3 (enExample) 2019-12-17
LT3319969T (lt) 2024-06-10
CA2990020C (en) 2024-02-27
EP3319969A1 (en) 2018-05-16
NZ738180A (en) 2024-04-26
EP4397665A2 (en) 2024-07-10
FI3319969T3 (fi) 2024-06-13
IL283184B2 (en) 2023-06-01
BR112018000297A2 (pt) 2018-09-04
KR20180026480A (ko) 2018-03-12
US10294242B2 (en) 2019-05-21
RS65593B1 (sr) 2024-06-28
WO2017007759A1 (en) 2017-01-12
IL256443B (en) 2021-05-31
MX2017017081A (es) 2018-08-16
ES2979111T3 (es) 2024-09-24
MX2021008145A (es) 2021-08-11
US12187739B2 (en) 2025-01-07
EP4397665A3 (en) 2024-08-21
EP3319969B1 (en) 2024-04-03
CN113354653A (zh) 2021-09-07
JP6917974B2 (ja) 2021-08-11
SI3319969T1 (sl) 2024-09-30
SMT202400213T1 (it) 2024-07-09
US20210094974A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
RU2765181C2 (ru) Полиморфная форма диарильного макроцикла
US11634422B2 (en) Inhibitors of activin receptor-like kinase
ES2656189T3 (es) Formas sólidas de un inhibidor macrocíclico de quinasa
WO2021023233A1 (zh) Egfr蛋白降解剂及其抗肿瘤应用
WO2012136099A1 (zh) 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN119371353B (zh) 泛kras抑制剂及其医药用途
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
HK1254492B (zh) 二芳基大环多晶型物
US20250129051A1 (en) Parp1 inhibitors and uses thereof
CN116589464A (zh) 嘧啶并环类化合物、其制备方法和应用
WO2001029043A1 (en) Ucs1025 derivatives